NeuroTech Newsletter #23
February 18, 2026
Executive Summary
Welcome to the 23rd edition of the Carter Sciences Neurotech Newsletter!
This month's edition captures the surging momentum in neurotechnology, from over $250 million in funding fueling innovations in brain-computer interfaces and neuromodulation to FDA clearances for wearable tremor therapies and expanding reimbursement for restorative neurostimulation. Clinical breakthroughs highlight implantable BCI advancements for stroke recovery, AI-driven diagnostics for early neurological detection, and promising neuromodulation trials for depression and autoimmune conditions, while strategic leadership appointments and collaborative launches underscore a maturing ecosystem poised for commercialization in mental health, sleep tech, and precision medicine—discover how these developments are reshaping the boundaries of human potential.
Check out the highlights below and as always send through any recommendations or feedback to chay@cartersciences.com
Funding News
EMOTIV Opens 2026 NeuroDiscovery Grant Applications
EMOTIV | February 12, 2026
EMOTIV has opened applications for its 2026 NeuroDiscovery Grant Program, aimed at advancing neuroscience, cognitive science, and brain-computer interface research through real-world applications. The program supports researchers, clinicians, and innovators by providing EEG technology and software grants totaling up to USD $20,000.
Envoy Medical Announces Pricing of Up to $78.0 Million Upsized Public Offering
Envoy Medical | February 11, 2026
Envoy Medical Inc. (NASDAQ: COCH), pioneered of fully implanted hearing solutions, announced the pricing of an upsized public offering of an aggregate of 75,000,000 shares of its Class A common stock accompanied by Series A-1 and A-2 common warrants.
Neurent Medical Raises €62.5 Million in Series C Financing
Neurent Medical | February 11, 2026
Neurent Medical announced the successful close of its oversubscribed Series C financing, raising €62.5 million ($74 million) to drive commercial expansion and broaden clinical evidence for NEUROMARK®, an innovative, minimally invasive solution to treat chronic rhinitis.
One Mind Accelerator Selects 14 Startups for 2026 Mental Health Cohort
One Mind Accelerator | February 9, 2026
The One Mind Accelerator has announced its fourth cohort for 2026, selecting 14 early-stage companies from a record number of applicants to advance mental health innovation. This cohort represents a diverse range of solutions incorporating technologies such as AI, biomarkers, neuroscience, and digital health.
Brain-Life Secures 10 Billion VND Investment from IDGX
Brain-Life | February 6, 2026
Brain-Life has secured a strategic investment of 10 billion VND from IDGX, marking a significant milestone in the company's development. This investment follows a period of close mentorship and shared strategic alignment, representing a vote of trust and responsibility to deliver value in neurotechnology.
Wisear Acquired by Naqi Logix to Advance Neural Interfaces
Wisear | February 5, 2026
Wisear, a developer of neural-interface earbuds enabling hands-free and voice-free control, has been acquired by Naqi Logix Inc. The acquisition integrates Wisear's expertise in signal processing and embedded AI with Naqi Logix, specializing in non-invasive neural interfaces via everyday wearables.
CraniUS Therapeutics Closes $20 Million Series B Round to Advance NeuroPASS Platform
CraniUS Therapeutics | January 29, 2026
CraniUS Therapeutics LLC announced it has raised $20 million in Series B financing to accelerate development of NeuroPASS™, a fully implantable, skull-embedded platform designed to bypass the blood-brain barrier (BBB) and enable targeted drug delivery and monitoring in the brain.
Omniscient Neurotechnology Raises $36 Million
Omniscient Neurotechnology | January 26, 2026
Omniscient Neurotechnology, a Sydney-based digital brain mapping connectomics company, raised $36 million in an ongoing Series D fundraising round led by National Reconstruction Fund Corporation NRFC with participation from OIF Ventures.
QV Bioelectronics Secures £4.5M for Glioblastoma Therapy Development
QV Bioelectronics | January 21, 2026
QV Bioelectronics has secured £4.5 million in investment and grant funding to advance the development of GRACE, its fully implantable electric field therapy for glioblastoma. The funding round was led by PXN Ventures North Of England via the GMC Life Sciences Fund and Empirical Ventures.
Enspire DBS Therapy Announces $10.3 Million Series B1 Financing
Enspire DBS Therapy | January 13, 2026
Enspire DBS Therapy, a clinical-stage company developing an implantable neuromodulation therapy for post-stroke recovery, announced that it has raised $10.3 million. Financing was led by Genesys Capital with participation from Cleveland Clinic and JobsOhio Ventures.
Industry Analysis
These funding developments, spanning grants, venture rounds, public offerings, and acquisitions totaling over $250 million, signal robust investor confidence in neurotechnology's therapeutic and commercial potential. Initiatives like Neurent Medical's €62.5 million Series C and Envoy Medical's $78 million offering highlight acceleration in minimally invasive treatments for conditions such as chronic rhinitis and hearing loss, potentially expanding market access and reducing healthcare costs while fostering innovation in brain-computer interfaces and neuromodulation, which could disrupt traditional neurology pipelines and attract further capital to scalable neurotech solutions.
Trend Conclusion
Emerging trends underscore a shift toward interdisciplinary and accessible neurotech, with grants from EMOTIV and accelerators like One Mind emphasizing early-stage mental health and BCI research, alongside strategic investments in wearables and implants as seen in Wisear's acquisition and CraniUS's $20 million round. This reflects growing focus on non-invasive, AI-integrated devices for diverse applications from stroke rehabilitation to glioblastoma therapy, indicating a maturing ecosystem prioritizing clinical validation and global commercialization to address unmet needs in neuroscience.
Regulatory & Reimbursement News
Encora Therapeutics Receives FDA 510(k) Clearance for Encora X1
Business Wire | February 12, 2026
Encora Therapeutics announced FDA 510(k) clearance for its Encora X1 wearable device, aimed at treating essential tremor. The clearance is backed by data from a randomized, sham-controlled clinical trial showing consistent reductions in tremor severity.
Mainstay Medical Announces Exclusive Coverage of ReActiv8
Business Wire | February 4, 2026
Mainstay Medical Holdings plc revealed that Blue Cross Blue Shield of North Dakota has implemented favorable coverage for ReActiv8 Restorative Neurostimulation therapy, targeting intractable chronic low back pain. Effective January 2026, the policy deems ReActiv8 the sole medically necessary option under specified conditions.
Regulatory Impact Analysis
The FDA's clearance of Encora X1 underscores accelerating regulatory support for wearable neuromodulation devices in movement disorders, likely spurring competition and patient adoption in the neurotechnology sector by offering less invasive alternatives to traditional therapies. Concurrently, the exclusive reimbursement for ReActiv8 by a regional insurer signals evolving payer dynamics for chronic pain treatments, which could influence national policies and enhance market viability for similar neurostimulation innovations, ultimately driving investment and broader clinical integration.
Regulatory Trend Conclusion
These announcements reveal a dual trend in neurotechnology regulation: expedited clearances for non-invasive devices addressing unmet needs in tremor management, alongside progressive reimbursement frameworks favoring targeted neurostimulation for pain, collectively indicating a maturing ecosystem that balances innovation with economic accessibility to propel industry growth.
Clinical News
CorTec Announces Successful Second Human Implantation of BCI System
CorTec GmbH | February 10, 2026
CorTec GmbH reported the successful second implantation of its Brain Interchange BCI system in an FDA-approved clinical trial for stroke patients at Harborview Medical Center, part of UW Medicine. This phase follows positive neurological improvements in the first participant.
Published Study Found Underlying Tremor Improvement with Cala TAPS Therapy
Cala Health | February 9, 2026
A retrospective analysis of the multicenter PROSPECT trial demonstrated that consistent use of Cala TAPS therapy reduced tremor severity in essential tremor patients at one- and three-month follow-ups, indicating sustained neurostimulation benefits.
Magnus Medical Announces First Patient Enrolled in SAINT PPD Study
Magnus Medical, Inc. | February 5, 2026
Magnus Medical enrolled the first patient in a DoD-funded, multicenter pivotal trial at UMass Chan Medical School to assess the SAINT neuromodulation system's safety and efficacy for postpartum depression.
A new way to communicate with neurons using focused ultrasound stimulation
Medical Xpress | February 3, 2026
Researchers observed neurons responding to focused ultrasound pulses via calcium signaling in preclinical models, highlighting a non-invasive neuromodulation technique that modulates brain activity with precision.
AI-Based Saliva Sensor Detects Neurological Disorders Accurately
Korea Institute of Materials Science | February 2, 2026
A collaborative study developed an AI-driven saliva sensor achieving 93.94% accuracy in differentiating epilepsy, schizophrenia, and Parkinson's disease, offering a non-invasive diagnostic tool for early neurological disorder detection through biomarker analysis.
Smelling Alzheimer's Early and Treating It With Sound
NeuroX / University of Lincoln | January 29, 2026
A collaboration between NeuroX and the University of Lincoln explores olfactory dysfunction as an early Alzheimer's biomarker, combined with sound-based therapeutic interventions, to enable pre-symptomatic detection.
Psilocybin-induced alterations in EEG power, connectivity and network dynamics
Progress in Neurobiology | January 27, 2026
This preclinical EEG study in healthy subjects revealed psilocybin decreases theta/alpha power while increasing beta/gamma power and connectivity in the default mode and parietal networks.
An auditory heartbeat stimulus can influence heart rate and psychological experience
Lyeons | January 27, 2026
A study on cardiac physiological coupling demonstrated that auditory heartbeat stimuli synchronize heart rate and reduce stress/anxiety in participants, providing a non-invasive method to modulate autonomic nervous system activity.
The curse of dimensionality in motor cortex
bioRxiv | January 26, 2026
This preclinical analysis using PCA on motor cortex neural data challenges the assumption of task-intrinsic dimensionality, showing that variance explained by principal components varies with recording duration and population size.
A multimodal sleep foundation model for disease prediction
Nature Medicine | January 6, 2026
Researchers developed a foundation model integrating polysomnography signals to predict diseases from sleep patterns, addressing standardization challenges and enabling multimodal analysis for early detection.
Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis
Nature Medicine | December 22, 2025
The RESET-RA phase III trial showed vagus nerve neuromodulation significantly reduced disease activity by modulating the inflammatory reflex and cytokine production, offering a novel bioelectronic therapy for autoimmune conditions.
Clinical Impact Analysis
These developments in neurotechnology underscore a transformative shift toward implantable and non-invasive interfaces, enhancing patient outcomes in stroke recovery, tremor management, and depression treatment while expanding diagnostic capabilities via AI and biomarkers. By integrating neuromodulation with precision medicine, the industry could reduce reliance on pharmaceuticals, lower treatment burdens, and improve accessibility for chronic neurological conditions, ultimately elevating standards in personalized patient care.
Research Trend Conclusion
Emerging trends reveal a surge in bioelectronic and neuromodulation innovations, from BCIs and ultrasound stimulation to vagus nerve therapies, alongside AI-driven diagnostics for early detection of disorders like Alzheimer's and Parkinson's. Multidisciplinary approaches combining EEG, sleep analysis, and psychedelics highlight a move toward holistic neural network modulation, promising accelerated clinical translations that bridge preclinical insights with real-world therapeutic efficacy in the neurotechnology landscape.
Commercial Collaborations and Launches
Powering the Future Within™ Podcast Launch
RL Medical | February 18, 2026
RL Medical has launched the Powering the Future Within™ podcast, a bi-weekly series exploring MedTech trends, implantable devices, and innovations in patient care through interviews with industry experts.
Galea Discovery Program Announcement
OpenBCI | February 18, 2026
OpenBCI's Galea Discovery Program provides discounted access to its biosensing system for elite researchers, targeting cognitive state detection and neurofeedback applications, with a Spring 2026 cohort deadline of February 28.
Nimbus Studio: Visual BCI Pipeline Builder
Nimbus | February 18, 2026
Nimbus has introduced Studio, a no-code visual builder for brain-computer interface pipelines, enabling researchers to design, test, and deploy experiments rapidly, reducing setup time by 10x.
e184 BAI Launches MEG Magnetometers for Brain-Computer Interfaces
e184 BAI | February 12, 2026
e184 BAI has launched sensitive magnetometers for magnetoencephalography to enhance brain-computer interfaces, focusing on human-AI collaboration.
ai6 Labs: Synergistic Neural AI Ecosystem Launch
Wearable Devices Ltd. | February 11, 2026
Wearable Devices Ltd. has launched ai6 Labs, a closed-loop ecosystem integrating AI-powered touchless sensing wearables to bridge human intent with digital reality.
XRHealth and NeuroVirt Announce Collaboration
XRHealth | February 10, 2026
XRHealth and NeuroVirt have formed a strategic partnership to integrate NeuroVirt's evidence-based XR rehabilitation games into XRHealth's platform, expanding neurorehabilitation offerings.
Nimbus Joins COALITION Neurotech for Collaborative Advancement
Nimbus | February 10, 2026
Nimbus has joined COALITION Neurotech, a collaborative network of industry professionals, clinicians, and researchers, to promote shared standards, regulatory engagement, and practical applications in BCI infrastructure.
Muse Brings Deep Sleep Stimulation Home
Muse | February 9, 2026
Muse has launched Deep Sleep Boost, an AI-driven feature on the Muse S Athena headband that uses EEG data to deliver targeted acoustic stimulation for slow-wave sleep enhancement.
CardiaCare Rebrands to StimCardio Medical
StimCardio Medical | February 4, 2026
CardiaCare has rebranded to StimCardio Medical to emphasize its non-invasive neuromodulation platform for home-based atrial fibrillation therapy, signaling a strategic pivot toward personalized neuro-cardiology.
Sleep Is Big Business: Market Growth and Trends
Substack | February 3, 2026
The global sleep market is expanding rapidly into a multi-billion-dollar ecosystem fueled by AI-enabled technologies, rising sleep disorder awareness, and integrated health solutions.
Market Impact Analysis
These developments intensify competition in brain-computer interfaces and neurorehabilitation by accelerating tool accessibility and collaborative standards, enabling faster innovation cycles and broader market entry for startups like e184 BAI and Wearable Devices, while established players like Muse and XRHealth expand therapeutic portfolios, potentially driving industry growth through AI integration and home-based solutions that lower barriers to adoption and enhance patient outcomes.
Commercial Trend Conclusion
A clear trend emerges toward ecosystem-building collaborations and AI-enhanced product launches in BCI and sleep neurotech, with programs like Galea Discovery fostering researcher partnerships and rebrands like StimCardio signaling specialized neuromodulation focus, indicating a shift to integrated, user-centric strategies that prioritize scalability, regulatory alignment, and interdisciplinary alliances to capture expanding wellness and rehab markets.
Leadership Appointments
Mark Gryzwa Appointed VP of Product Development at SecondWave Systems
SecondWave Systems | February 12, 2026
Mark Gryzwa has joined SecondWave Systems, Inc. as Vice President of Product Development, bringing expertise in medical device product development to lead key initiatives.
iota Biosciences Appoints Engineering and Marketing Leaders
iota Biosciences | February 12, 2026
iota Biosciences, Inc. has appointed Lee Travis as leader of its Engineering organization, leveraging nearly 30 years of experience in medical device engineering and product development.
Salvia Appoints Daniel Balkcom as VP U.S. Commercial Strategy
Salvia BioElectronics | February 11, 2026
Salvia BioElectronics B.V. has appointed Daniel Balkcom as Vice President of U.S. Commercial Strategy and Operations, where he will lead and define the strategic direction of the company's U.S. market expansion.
Motif Neurotech Appoints Adnan Ashraf to UK Team
Motif Neurotech | February 10, 2026
Motif Neurotech has appointed Adnan Ashraf to its UK team in London, bringing over a decade of experience in radar, wireless sensor networks, blockchain-based IoT, and edge AI wearables.
Neurotrack Promotes Russell B. to Chief Scientific Officer
Neurotrack | February 6, 2026
Neurotrack has promoted Russell B. to Chief Scientific Officer, recognizing his strategic and scientific expertise to drive research, foster collaboration, and support commercial success.
Gilde Healthcare appoints Matthew Stork as CEO
Gilde Healthcare | February 5, 2026
The neuroimaging group of Gilde Healthcare has appointed Matthew Stork as CEO with over 25 years of MedTech executive experience and Maarten Jaspers as Finance Director to enhance organizational leadership.
Brent Madigan Joins Sense Neuro as VP of Sales
Sense Neuro Diagnostics | February 4, 2026
Brent Madigan has joined Sense Neuro Diagnostics as Vice President of Sales, contributing his expertise to drive growth in the company's neurotechnology solutions focused on diagnostics.
Craig Gallivan Joins Beacon Biosignals
Beacon Biosignals | February 2, 2026
Craig P. Gallivan, holding an MBA with expertise in MedTech and AI diagnostics strategy, has joined Beacon Biosignals as National Vice President of Clinical Sales to oversee clinical sales operations.
Jeffrey Philippson Joins CoMind as Senior Manager
CoMind | February 2, 2026
Jeffrey Philippson has joined CoMind as Senior Manager of Systems and Verification & Validation, applying data-driven approaches to improve decision-making in medical device development.
Tiffany Dunn Joins Boston Scientific
Boston Scientific | February 1, 2026
Tiffany Dunn has joined Boston Scientific Neuromodulation as Senior Director of Medical Education, overseeing initiatives to advance education within the neuromodulation division.
NeuroEM Therapeutics Appoints Dr. W. Scott Burgin as CMO
NeuroEM Therapeutics | January 30, 2026
NeuroEM Therapeutics, a clinical-stage biotechnology company pioneering radio frequencies to reverse Alzheimer's disease, has appointed Dr. W. Scott Burgin as its first Chief Medical Officer.
Subsense Inc. Appoints Gary Lo as New CFO
Subsense Inc. | January 30, 2026
Subsense Inc. has appointed Gary Lo, CPA, with over 30 years in finance and fundraising for deep-tech and life sciences, as Chief Financial Officer to shape financial strategy amid development of non-surgical brain-computer interfaces.
Leadership Impact Analysis
These recent leadership appointments across the neurotechnology sector signal a strategic push toward commercialization and innovation, with hires like Daniel Balkcom at Salvia and Brent Madigan at Sense Neuro enhancing U.S. market penetration and sales capabilities for neuromodulation and diagnostics firms. Companies such as iota Biosciences and Gilde Healthcare's neuroimaging group are bolstering engineering and financial expertise to accelerate product roadmaps and scaling, potentially intensifying competition in cognitive health and brain-computer interfaces while driving industry-wide advancements in regulatory approval and investor confidence amid evolving market dynamics.
Executive Trend Conclusion
A clear trend emerges in recruiting seasoned MedTech veterans for VP-level and C-suite roles, emphasizing expertise in engineering, sales, and finance to support rapid commercialization of neurotech solutions like wearables and neuromodulation therapies. This focus on experienced leaders from adjacent fields underscores a maturing industry prioritizing scalable growth and strategic U.S. expansion over pure R&D, likely fostering greater integration of AI and non-invasive technologies to address unmet needs in Alzheimer's, migraine, and cognitive diagnostics.
Closing Thoughts
Key Strategic Insights
This edition's neurotechnology landscape reveals a robust infusion of over $250 million in funding across grants, venture rounds, and acquisitions, underscoring investor enthusiasm for scalable solutions in brain-computer interfaces (BCIs), neuromodulation, and mental health innovations, as seen in EMOTIV's NeuroDiscovery grants, Neurent Medical's €62.5 million Series C, and Wisear's acquisition by Naqi Logix; these financial tailwinds align with FDA clearances for wearables like Encora X1 for essential tremor and exclusive reimbursements for ReActiv8 in chronic pain, signaling regulatory and payer validation that de-risks commercialization and expands market access for non-invasive therapies, while clinical milestones—such as CorTec's second BCI implant and AI-driven saliva sensors for neurological diagnostics—demonstrate tangible efficacy in stroke recovery, tremor reduction, and early disease detection, collectively positioning neurotech as a high-growth sector disrupting traditional neurology with patient-centric, AI-enhanced devices that promise cost savings and improved outcomes.
Cross-Functional Analysis
Funding fuels clinical advancements like Enspire's $10.3 million for DBS-enabled stroke rehab and QV Bioelectronics' £4.5 million for glioblastoma therapy, which in turn secure regulatory nods and reimbursements as evidenced by Mainstay Medical's Blue Cross coverage, enabling commercial launches such as Muse's AI-driven sleep stimulation and Nimbus Studio's no-code BCI builder; leadership hires, including Salvia's VP of U.S. Commercial Strategy and iota Biosciences' engineering head, bridge R&D with market execution, fostering collaborations like XRHealth-NeuroVirt's XR neurorehabilitation partnership and COALITION Neurotech's standards push, while interdisciplinary trends—from psilocybin EEG studies to vagus nerve modulation for rheumatoid arthritis—highlight synergies between neuroscience, AI, and bioelectronics, creating a cohesive ecosystem where early-stage grants evolve into global expansions, reducing silos and accelerating translation from bench to bedside.
Future Outlook & Recommendations
Looking ahead, the neurotech sector is primed for explosive growth through deeper AI integration in diagnostics and wearables, broader adoption of non-invasive BCIs for mental health and sleep disorders, and expanded indications like postpartum depression via Magnus Medical's SAINT trials, with market projections for sleep tech alone reaching multi-billion status; executives should prioritize strategic alliances, as seen in One Mind Accelerator's mental health cohort and Galea Discovery Program, to navigate regulatory hurdles and secure reimbursements, while investing in scalable platforms like e184 BAI's MEG magnetometers to capture consumer and enterprise markets—recommend forming cross-functional teams blending clinical expertise with commercial acumen to capitalize on emerging trends in ultrasound neuromodulation and olfactory biomarkers for Alzheimer's, ensuring agility in a landscape shifting toward personalized, home-based therapies that could redefine preventive neurology.
Final Word
As neurotechnology bridges the gap between neural insight and everyday impact, this week's momentum heralds an era where innovation not only treats but anticipates neurological challenges, demanding bold leadership to unlock unprecedented value for patients and stakeholders alike.
© 2026 Carter Sciences. All rights reserved.
This newsletter is compiled for professionals in the Neurotechnology industry.
